Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

32 Results

Guidelines and Advice

Systemic Therapy for Advanced Gastric and Gastro-Esophageal Carcinoma

Status: In-Review
ID: GL 2-26
Version: 3

Aug 2022

Guidelines and Advice

Systemic therapy of denosumab in altering surgical outcomes in patients with giant cell tumour of bone

Status: Current
ID: ES 11-13

Feb 2021

Guidelines and Advice

Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma

Status: Current
ID: GL 4-18
Version: N/A

Sep 2020

Guidelines and Advice

Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma

Status: Current
ID: GL 4-1
Version: 2

Jan 2021

Guidelines and Advice

The Use of Bevacizumab in Metastatic Breast Cancer

Status: Archived
ID: CED 12

Apr 2009

Guidelines and Advice

Bevacizumab for Recurrent Glioblastoma Multiforme (GBM)

Status: Archived
ID: CED 19

Jul 2010

Guidelines and Advice

Dose-intensive Chemotherapy with Growth Factor or Autologous Bone Marrow/Stem Cell Transplant Support in Advanced or Metastatic Adult Soft Tissue Sarcoma

Status: Archived
ID: 11-5

Sep 2011

Guidelines and Advice

Position Statements for the Implementation of Oncology Biosimilars from the pan-Canadian Clinical Operations Working Group

Status: Current
Version: 1

Aug 2019

Pages